ライフサイエンスコーパス: controlled study

1 domized, double-masked, multicenter, placebo-controlled study.

2 ter, open-label, dose-escalation, fellow-eye-controlled study.

3 ns has not been assessed within a randomized controlled study.

4 lticenter, randomized, double-blind, placebo-controlled study.

5 om healthy donors in a double-blind, placebo-controlled study.

6 ed melanoma has not been tested in a phase 3 controlled study.

7 as well tolerated in a double-blind, placebo-controlled study.

8 ntinuous levodopa delivery in a double-blind controlled study.

9 vestigated in a pilot, double-blind, placebo-controlled study.

10 tients treated with ivacaftor in the placebo-controlled study.

11 patients who received placebo in the placebo-controlled study.

12 had received active treatment in the placebo-controlled study.

13 ase studies, cohort studies, and one placebo-controlled study.

14 le-dummy, 3-arm, parallel, active-comparator controlled study.

15 Randomized, double-blind, placebo-controlled study.

16 ctive, double-blind, multicenter, randomized controlled study.

17 ctive, 1:1 randomized, double-blind, placebo-controlled study.

18 e, parallel-group, double-blind, randomized, controlled study.

19 dding in a randomized, double-blind, placebo-controlled study.

20 ansplantation were examined in a randomized, controlled study.

21 7.1 years) in a double-blind cross-over sham-controlled study.

22 This was a randomized, double-blind, placebo-controlled study.

23 ck needs to be studied in further randomized controlled studies.

24 e-blind, parallel-group, placebo- and active-controlled studies.

25 res are frequently conducted without closely controlled studies.

26 infection has not been shown in prospective controlled studies.

27 was limited to rigorously conducted and well-controlled studies.

28 further investigation in larger, randomised controlled studies.

29 impact in drug binding sites merits further controlled studies.

30 ) and 15 (36.6%), respectively, were vehicle-controlled studies.

31 ults of this study in the context of 4 other controlled studies (1 negative and 1 positive in a prede

32 ICIPANTS: In a phase 2 double-blind, placebo-controlled study, 159 patients (median [SD] age, 64 [8]

33 In a prospective, 3-center, nonrandomized, controlled study, 2 sequential groups of P2Y12 inhibitor

34 double-blind, randomized, crossover, placebo-controlled study, 22 subjects with DSM-IV treatment-resi

35 In this double-blind, placebo-controlled study, 40 healthy male subjects were randomiz

36 In a randomized double-blind placebo-controlled study, 56 patients with moderate-severe LAR t

37 In a randomized, double-blind, placebo-controlled study, 60 patients with fibrotic IIP and righ

38 In a 12-week, double-blind, placebo-controlled study, 60 treatment-resistant children and ad

39 In this double-blind, randomized, placebo-controlled study 68 subjects aged 12 to 45 years with al

40 lticenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (a

41 s 12-wk, double-blinded, randomized, placebo-controlled study, 76 vegans received either a placebo (n

42 In this randomized, controlled study, 90 patients with recently diagnosed ac

43 In controlled studies, a single springtime application of a

44 In a randomized, blinded, placebo-controlled study, adults were challenged with monovalent

45 a multicenter, 28-day, open-label randomized controlled study, adults with moderate cancer pain were

46 This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biol

47 rane conductance regulator (CFTR) in placebo-controlled studies and patients aged 6-11 years with cys

48 bservational data, with very few randomized, controlled studies, and association does not prove causa

49 -1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised,

50 Results from large scale placebo-controlled studies are awaited.

51 Larger controlled studies are essential to prove efficacy

52 lmonary fibrosis, although data from placebo-controlled studies are lacking.

53 promising alternative treatment option, but controlled studies are lacking.

54 n the current body of literature, large well-controlled studies are necessary to better quantify the

55 Prospective controlled studies are necessary to confirm the benefici

56 Prospective and controlled studies are necessary to evaluate the efficac

57 of our findings on Plasmodium transmission, controlled studies are needed in participants with gamet

58 Further controlled studies are needed to assess the safety and e

59 Larger case series or even controlled studies are needed to confirm the efficacy of

60 Larger controlled studies are needed to establish this relation

61 Controlled studies are needed to substantiate findings.

62 Large-scale, randomized, controlled studies are needed to substantiate these find

63 food allergy is not clear, and more placebo-controlled studies are needed.

64 f patients with fecal incontinence, but more controlled studies are needed.

65 lators achieve high response rates, although controlled studies are needed.

66 Further randomized controlled studies are required to assess the effect of

67 llow-up and in particular randomized placebo-controlled studies are required to confirm these finding

68 Larger randomized controlled studies are required to confirm these results

69 More data from randomized controlled studies are warranted.

70 Further controlled studies are warranted.

71 entions and rates of breastfeeding from well-controlled studies as well as for harms related to breas

72 This placebo-controlled study assessed the effects of the once-daily

73 study, a multicentre, open-label, randomised controlled study at 19 specialist paediatric surgery cen

74 We did this double-blind, placebo-controlled study at 35 hospitals in Canada, France, Germ

75 e did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries worldwi

76 mised, double-blind, parallel-group, placebo-controlled study at 49 hospitals in seven European count

77 We did this factorial randomised controlled study at Mulago Hospital, Uganda.

78 e complexity of the disease and the very few controlled studies available.

79 In this first placebo-controlled study, canakinumab was effective in patients

80 edline, PubMed, Cochrane Central Register of Controlled Studies, CINAHL Plus, AMED, EMBASE and HuGE N

81 Eight controlled studies compared the effectiveness of no IVC

82 ulation of lipolysis.A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosapentaenoic

83 review was conducted to identify randomized controlled studies comparing nurse-led self-management i

84 glycated haemoglobin targets and randomised controlled studies comparing the efficacy of pump treatm

85 after 6 months in a prospective, randomised, controlled study comparing best medical therapy (BMT, n=

86 In this randomized, controlled study comparing the flapless and traditional

87 In two multicenter, crossover, randomized, controlled studies conducted under free-living home cond

88 Double-blind, placebo-controlled study conducted among 380 patients who underw

89 omized, double-blind, placebo- and ezetimibe-controlled study conducted between January and December

90 ine, was assessed in a double-blind, placebo-controlled study conducted from September 2014 to April

91 ssed in a multicentre, double-blind, placebo-controlled study conducted in 483 patients with BP-induc

92 luded in a randomized, double-blind, placebo-controlled study conducted in Switzerland between 2005 a

93 That nested-case controlled study consisted of specimens specifically cho

94 In a double-blind placebo-controlled study, critically ill intubated patients were

95 In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) with >/=4 a

96 This large, prospective, randomized, controlled study demonstrates noninferiority of CB ablat

97 er using a monocenter, double-blind, placebo-controlled study design.

98 monkeys were used in a double-blind, placebo-controlled study design.

99 trial is a randomized, double-blind, placebo-controlled study, designed to investigate the effects of

100 This prospective randomized controlled study (DISCOVER trial) included 152 patients

101 Dropout rates in sublingual immunotherapy controlled studies do not appear to be a major problem w

102 three-part, randomised, multicentre, placebo-controlled study done at 22 centres in the USA, UK, Cana

103 a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countries (Arg

104 omised, parallel group, double-blind, active-controlled study done in 159 sites across 14 countries.

105 se concentration in 2 randomized, crossover, controlled studies (double-blinded for the supplements),

106 In this open-label, randomised, controlled study, eligible healthy infants 6-12 weeks of

107 s phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with

108 uble-blind, randomized, multicenter, placebo-controlled study, established the efficacy and safety of

109 lticenter, randomized, double-blind, placebo-controlled study evaluated 3 regimens of grass allergen

110 A randomized, double-blind, placebo-controlled study evaluated an adjuvanted bivalent intram

111 This phase 1/2, randomized, placebo-controlled study evaluated the immunogenicity and safety

112 This phase III, randomized, placebo (saline)-controlled study evaluated the safety of rhC1INH 50 IU/k

113 This randomized controlled study evaluated, in persons with a high risk

114 Asthma-specific outcomes from randomized, controlled studies evaluating INCS medications in patien

115 ECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sitagliptin

116 We conducted a comprehensive search for controlled studies, evaluating the association between m

117 There are limited well-controlled studies examining the effectiveness of system

118 -D cell oncology models and allow for better-controlled studies for drug discovery.

119 arried out a double-blind randomized placebo-controlled study for 16 weeks, followed by an open-label

120 red trial, we designed this first randomized controlled study for the comparison of TVC and NC.

121 No controlled studies had as primary goal the changes in HD

122 tive method for preventing infection, but no controlled study has been published in the United States

123 A new randomized, double-blind controlled study has found that playing a video game mod

124 of antimicrobial-resistant bacteria, but no controlled study has tested the effect of rapid screenin

125 Few well-controlled studies have comprehensively examined the eff

126 Several controlled studies have confirmed that an intense approa

127 However, controlled studies have demonstrated antidepressant acti

128 However, some well-controlled studies have found regionally greater gray ma

129 Several randomised placebo-controlled studies have shown that UDCA improves transpl

130 re included in this single-mask, randomized, controlled study if probing depth (PD) was </=3 mm and a

131 Findings should be validated in larger, controlled studies in animals and humans using a range o

132 necessary to inform the design of randomized controlled studies in at-risk populations.

133 periodontal disease have not been tested in controlled studies in low-income populations.

134 decreases only slightly, demonstrating that controlled studies in vitro provide an excellent startin

135 performed a blinded, randomized and placebo-controlled study in 11 conscious patients (nine men, two

136 in a single-blind (patients masked), placebo-controlled study in 12 men with clinically stable asthma

137 In a single-center, randomized, open, controlled study in 8 healthy volunteers, 50 mg purified

138 ase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma, non-Ho

139 multihospital, multidepartmental prospective controlled study in an urban academic setting.

140 In summary, this is the first prospective, controlled study in CLL patients that shows a role of co

141 lticentre, double-blind, randomised, placebo-controlled study in four hospitals in Kenya (two rural h

142 In a subsequent double-blind, placebo-controlled study in healthy volunteers, we aimed at prov

143 This was a randomized, placebo-controlled study in patients with International Federati

144 , phase 3, randomised, double-blind, placebo-controlled study in patients with tuberous sclerosis com

145 We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behcet's syn

146 This was a randomized, double-blind, placebo-controlled study in which 68 individuals were randomly a

147 an open-label, randomised, active-comparator controlled study, in which participants were inoculated

148 A double-blind, randomized, placebo-controlled study included 63 healthy female volunteers (

149 This randomized, double-blind, controlled study included Canadian and Spanish patients

150 A number of well-controlled studies indicate that probiotics, particularl

151 We discuss how controlled studies involving direct perturbations of mic

152 series of randomized, double-blind, placebo-controlled studies involving subjects with unipolar or b

153 a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open label e

154 A phase 1 and 2 randomized, blinded, placebo-controlled study involving 65 patients with ischemic car

155 lticenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the

156 Prospective case-controlled study involving patient and caregiver complet

157 a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthr

158 e conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously trea

159 Replication of such results in well controlled studies is essential to clarify the effects o

160 t evidence from natural experiments or other controlled studies is scarce.

161 results can be confirmed by larger and well-controlled studies, it may have considerable programmati

162 (January 1, 1996, through May 31, 2012) for controlled studies lasting 2 weeks or longer in children

163 For music interventions, we pooled controlled studies measuring health outcomes (eg, pain,

164 ed from two randomized double-blind, placebo-controlled studies: MENSA (NCT01691521: 32-week treatmen

165 above mainly because there is a lack of well-controlled studies, most information comes from small st

166 This randomized, placebo-controlled study (NCT00985725) enrolled 143 adults (18-5

167 Few placebo-controlled studies of antibiotics have been done, and ov

168 , from two randomised, double-blind, placebo-controlled studies of at least 32 weeks duration (NCT010

169 Few long-term or controlled studies of bariatric surgery have been conduc

170 A DHIM could allow experimentally controlled studies of candidate therapeutics in preselec

171 990 to September 2012) were searched, and 47 controlled studies of fair methodological quality were i

172 Few controlled studies of in-store marketing strategies to p

173 echnique can enable more advanced and better-controlled studies of ion transport in CDI systems, whic

174 Controlled studies of patients receiving enteral nutriti

175 led from three phase III randomized, placebo-controlled studies of pirfenidone for IPF (the two CAPAC

176 ase, we analysed the results from randomised controlled studies of prophylactic cranial irradiation i

177 s through 24 June 2013 to locate prospective controlled studies of psychosocial interventions deliver

178 To our knowledge, no controlled studies of the effects of long-term growth ho

179 There have been few controlled studies of these therapies, which have been l

180 cluded in the review if they were randomized controlled studies of whole-grain compared with a non-wh

181 We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe C

182 ndomized Phase I/II, observer-blind, placebo-controlled study of 12 healthy, H pylori-negative adults

183 fteen participants with atopy completed this controlled study of 2 hours of filtered air or DE (300 m

184 rticipants: Multicenter double-blind placebo-controlled study of 260 nonneutropenic, nontransplanted,

185 erformed a randomized, double-blind, placebo-controlled study of 44 adults with IBS and diarrhea or a

186 We conducted a randomized, controlled study of 441 patients to assess whether long-

187 onducted a randomized, double-blind, placebo-controlled study of 66 optimally-treated T2DM patients w

188 embers of the dyad.We conducted a randomized controlled study of 97 mother-infant dyads.

189 ticenter, randomized, double-masked, placebo-controlled study of acetazolamide in 165 participants wi

190 id a nationwide, prospective, non-randomised controlled study of adolescents (aged 13-18 years) with

191 from 386 patients enrolled in a randomized, controlled study of antibiotic efficacy.

192 d this prediction empirically with a placebo-controlled study of cholinesterase inhibition.

193 In a randomized controlled study of consecutive patients undergoing ERCP

194 The results of this first randomized controlled study of DBS for the treatment of TRD did not

195 nitiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC.

196 reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT) in whi

197 d-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, corticostero

198 We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor

199 Furthermore, controlled study of infection has been hampered by the l

200 This work presents a controlled study of low-density lipoprotein (LDL) and hi

201 This forms a basis for a controlled study of many-body dynamics driven by higher-

202 tandard treatment, yet no randomized placebo-controlled study of medical IOP reduction has been under

203 of life.A double-blind, randomized, placebo-controlled study of newborn infants assigned to a standa

204 e performed a phase 3, multicenter, baseline-controlled study of patients with acute or acute recurre

205 work in a randomized, double-blind, placebo-controlled study of patients with bipolar depression.

206 ndertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcino

207 In a placebo-controlled study of patients with IBS, a low FODMAP diet

208 F were enrolled in a multicenter, randomized controlled study of PV isolation using either the VGLB o

209 We conducted a case-controlled study of the associations of CCR5-Delta32 het

210 d, multicenter, randomized, Active treatment-controlled study of the efficacy and safety of 0.5 mg an

211 d, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg an

212 r, Randomized, Double-masked, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizum

213 (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of T

214 r diseases; however, results from randomized controlled studies on blood lipids are inconsistent, pot

215 An additional randomized, crossover, controlled study on 16 volunteers consuming constituent

216 In an initial, randomized controlled study on elderly subjects with increased deme

217 Two retrospective, controlled studies, one uncontrolled study and 79 case r

218 gle-centre, double-blind, crossover, placebo-controlled study, partial responders taking optimised PP

219 omised, double-blind, parallel-group, active-controlled study, patients aged 18 years or older with A

220 s phase 2A double-blind, randomised, placebo-controlled study, patients aged 18 years or older with c

221 tigation followed by a double-blind, placebo-controlled study, patients with allergic rhinitis were t

222 In this controlled study population of patients with retinoblast

223 In addition, vehicle- or placebo-controlled studies predominate over head-to-head compari

224 2) Forty-five controlled studies provided outcome analysis on the use

225 A mix of anecdotal and more controlled studies provides some support for this view;

226 This large randomized controlled study provides strong support for the efficac

227 rt, parallel group, double-blind, randomised controlled studies, reSURFACE 1 (at 118 sites in Austral

228 Larger, randomized controlled studies should be performed to further guide

229 Further controlled studies should evaluate its efficacy and safe

230 vertheless, early enthusiasm was tempered by controlled studies showing that antibiotics did not serv

231 ted by case reports, case series and a small controlled study showing the efficacy of anticoagulant t

232 This prospective, randomized, controlled study tested the hypothesis that an invasive

233 The authors conducted a review of randomized controlled studies testing the efficacy of adding a beha

234 The authors conducted a review of randomized controlled studies testing the efficacy of adding a beha

235 however, requires more comprehensive, better-controlled studies than have been published to date.

236 We searched multiple databases for controlled studies that enrolled pregnant women with chr

237 o phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effe

238 This was the first placebo-controlled study that also controlled for the confoundin

239 We analyzed data from a phase 2, placebo-controlled study that evaluated the efficacy and safety

240 Here, we report a double-blind, placebo-controlled, study that examined specific effects of nora

241 In this randomized, double-blind, placebo-controlled study the safety, tolerability, and clinical

242 This randomized, double-blind, placebo-controlled study (TL7116958) was conducted over two poll

243 RSS, suggesting a continued need for placebo-controlled studies to establish the clinical benefit of

244 a 6-month, randomized, double-blind, placebo-controlled study to assess safety, tolerability, and eff

245 onducted a randomized, double-blind, placebo-controlled study to assess whether raltegravir intensifi

246 This is the first randomized, placebo-controlled study to demonstrate that antimycobacterial t

247 This is the first randomized controlled study to demonstrate that resistance training

248 We performed a randomized, placebo-controlled study to determine its effects on symptoms an

249 We performed a large, multicenter randomized controlled study to determine the comparative efficacy o

250 We performed a placebo-controlled study to determine whether a delayed-release

251 onducted a double-blind, randomized, placebo-controlled study to evaluate the effect of gallopamil on

252 a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of

253 A randomized, double-blind, placebo-controlled study to evaluate the impact of oral serum-de

254 RYTON (Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness

255 (Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness

256 re, we report the first double-blind placebo-controlled study to examine the effects of MDMA on emoti

257 d a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients

258 ur results support the need for a randomized controlled study to investigate alternative antiplatelet

259 s were randomized in a double-blind, placebo-controlled study to receive 500 index of reactivity (IR)

260 This prospective controlled study took place at a clinical research cente

261 Of five randomised controlled studies, two showed significantly higher quit

262 In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asia, Austr

263 healthy older subjects in a randomized, sham-controlled study using a cross-over design.

264 We performed a randomized, placebo-controlled study using C1-INH in highly sensitized renal

265 this interaction, we conducted a randomized controlled study using the baboon (Papio anubis) to anal

266 A systematic review of randomized controlled studies was conducted.

267 A single-center parallel-group randomized controlled study was completed.

268 domized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in four cou

269 prospective, single-center, cross-sectional controlled study was conducted at the French National Re

270 This randomized, double-blind, sham-controlled study was conducted at the Naval Air Station

271 This prospective interocularly controlled study was conducted between February 1 and De

272 prospective, multicenter randomized placebo-controlled study was conducted in 120 subjects from Lati

273 Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet adm

274 This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America,

275 hree-stage randomised, double-blind, placebo-controlled study was done at 59 clinical sites in the US

276 ulticenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficac

277 The aim of this prospective randomized controlled study was to evaluate the safety and effectiv

278 im of this randomized, double-blind, placebo-controlled study was to test the hypothesis that anodal

279 A double-blind, randomized, controlled study was undertaken to determine whether com

280 In a double-blind, placebo-controlled study we examined approach-avoidance motor re

281 In this exploratory, double-blind, placebo-controlled study we recruited male patients (>/=5 years

282 In this randomized controlled study, we aimed to determine whether a high-e

283 lticenter, randomized, double-blind, placebo-controlled study, we assessed larazotide acetate 0.5, 1,

284 ur 6 week, randomised, double-blind, placebo-controlled study, we enrolled adults (aged >/=40 years)

285 In this randomized, controlled study, we investigated the effects of lowerin

286 In this double-blind, placebo-controlled study, we randomly assigned 31 patients with

287 In this randomized, double-blind, placebo-controlled study, we randomly assigned 32 HSCT recipient

288 is phase 3, multicentre, randomised, placebo-controlled study, we randomly assigned adults with HCV g

289 In this phase 2, controlled study, we randomly assigned patients with acq

290 single-centre (Leicester, UK), prospective, controlled study, we selected cases of natural and non-s

291 In a placebo-controlled study, we used arterial spin labeling to meas

292 Future controlled studies will be required to identify strategi

293 A sequential gatekeeping strategy controlled study-wise type 1 error for serum ferritin, t

294 c populations have been tested in randomised controlled studies with age-appropriate cohorts.

295 animals is less invasive and enables better-controlled studies with more immediate translation to th

296 We designed a prospective controlled study with 2 sequential cohorts of participan

297 This prospective randomized controlled study with 975 nontunneled central venous cat

298 olled in a double-blind, randomized, placebo-controlled study with pexacerfont (300 mg/day for 7 days

299 his hypothesis via a double-blinded, placebo-controlled study with the dopamine receptor agonists cab

300 Very few prospective controlled studies, with limited quality of evidence, ex